TW201111378A - Substituted (heteroarylmethyl) thiohydantoins - Google Patents

Substituted (heteroarylmethyl) thiohydantoins Download PDF

Info

Publication number
TW201111378A
TW201111378A TW099127804A TW99127804A TW201111378A TW 201111378 A TW201111378 A TW 201111378A TW 099127804 A TW099127804 A TW 099127804A TW 99127804 A TW99127804 A TW 99127804A TW 201111378 A TW201111378 A TW 201111378A
Authority
TW
Taiwan
Prior art keywords
group
methyl
trifluoromethyl
keto
dimethyl
Prior art date
Application number
TW099127804A
Other languages
English (en)
Chinese (zh)
Inventor
Ulrich Luecking
Arwed Cleve
Bernard Haendler
Hortensia Faus
Silke Koehr
Horst Irlbacher
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of TW201111378A publication Critical patent/TW201111378A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW099127804A 2009-09-11 2010-08-19 Substituted (heteroarylmethyl) thiohydantoins TW201111378A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17

Publications (1)

Publication Number Publication Date
TW201111378A true TW201111378A (en) 2011-04-01

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099127804A TW201111378A (en) 2009-09-11 2010-08-19 Substituted (heteroarylmethyl) thiohydantoins

Country Status (28)

Country Link
US (1) US20120251551A1 (enEXAMPLES)
EP (1) EP2475653A1 (enEXAMPLES)
JP (1) JP2013504523A (enEXAMPLES)
KR (1) KR20120065396A (enEXAMPLES)
CN (1) CN102639523A (enEXAMPLES)
AR (1) AR078166A1 (enEXAMPLES)
AU (1) AU2010294588A1 (enEXAMPLES)
BR (1) BR112012005526A2 (enEXAMPLES)
CA (1) CA2773591A1 (enEXAMPLES)
CL (1) CL2012000623A1 (enEXAMPLES)
CO (1) CO6511228A2 (enEXAMPLES)
CR (1) CR20120113A (enEXAMPLES)
CU (1) CU20120042A7 (enEXAMPLES)
DO (1) DOP2012000063A (enEXAMPLES)
EA (1) EA201200473A1 (enEXAMPLES)
EC (1) ECSP12011716A (enEXAMPLES)
IL (1) IL218390A0 (enEXAMPLES)
IN (1) IN2012DN02081A (enEXAMPLES)
MA (1) MA33566B1 (enEXAMPLES)
MX (1) MX2012002977A (enEXAMPLES)
NZ (1) NZ598643A (enEXAMPLES)
PE (1) PE20121180A1 (enEXAMPLES)
PH (1) PH12012500497A1 (enEXAMPLES)
SG (1) SG178919A1 (enEXAMPLES)
TN (1) TN2012000108A1 (enEXAMPLES)
TW (1) TW201111378A (enEXAMPLES)
UY (1) UY32882A (enEXAMPLES)
WO (1) WO2011029537A1 (enEXAMPLES)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501650B1 (en) 2010-02-17 2018-11-07 Takeda Pharmaceuticals Co Heterocyclic compound
WO2011150457A2 (en) * 2010-06-01 2011-12-08 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
PT2794627T (pt) 2011-12-22 2018-12-19 Janssen Biopharma Inc Nucleósidos substituídos, nucleótidos e análogos dos mesmos
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9422323B2 (en) 2012-05-25 2016-08-23 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
TW201418243A (zh) 2012-11-15 2014-05-16 Bayer Pharma AG 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
LT2935303T (lt) 2012-12-21 2021-03-25 Janssen Biopharma, Inc. 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (zh) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 一种二芳基硫代乙内酰脲衍生物及其应用
EP4257591A3 (en) * 2013-12-11 2023-11-22 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
WO2015169677A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
EP3359544B1 (en) 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
EP3601253B1 (en) 2017-03-28 2021-09-15 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CA3057891A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US20200148635A1 (en) 2017-05-18 2020-05-14 Pi Industries Ltd. Formimidamidine compounds useful against phytopathogenic microorganisms
KR102764122B1 (ko) 2018-02-13 2025-02-05 바이엘 악티엔게젤샤프트 미만성 거대 b-세포 림프종을 치료하기 위한 5-플루오로-4-(4-플루오로-2-메톡시페닐)-n-[4-[(s-메틸술폰이미도일)메틸]피리딘-2-일]피리딘-2-아민의 용도
WO2020209933A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
AU2021209875A1 (en) * 2020-01-21 2022-08-11 Georgia Tech Research Corporation Aryl hydantoin heterocycles and methods of use
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法
WO2025103470A1 (zh) * 2023-11-17 2025-05-22 中国药科大学 作为雄激素受体(ar)拮抗剂的化合物及其应用
CN120309588B (zh) * 2025-06-10 2025-08-12 上海健康医学院 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO2000017163A1 (fr) 1998-09-22 2000-03-30 Yamanouchi Pharmaceutical Co., Ltd. Derives de cyanophenyle
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CA2529292A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
BRPI0414918A (pt) 2003-09-30 2006-11-07 Janssen Pharmaceutica Nv compostos de benzoimidazola
WO2005061463A1 (en) 2003-12-23 2005-07-07 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
DE602005027213D1 (de) 2004-08-03 2011-05-12 Chugai Pharmaceutical Co Ltd Neue imidazolidinderivate
EP1790640A4 (en) * 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
ES2343812T3 (es) 2004-12-03 2010-08-10 F. Hoffmann-La Roche Ag Derivados de piperidina 3-sustituidos como antagonistas del receptor h3.
PL2444085T3 (pl) * 2005-05-13 2015-07-31 Univ California Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
KR101600230B1 (ko) 2006-03-29 2016-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
WO2009055053A2 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
EA201200473A1 (ru) 2012-10-30
CA2773591A1 (en) 2011-03-17
CU20120042A7 (es) 2012-06-21
CL2012000623A1 (es) 2012-09-14
MX2012002977A (es) 2012-04-30
KR20120065396A (ko) 2012-06-20
UY32882A (es) 2011-04-29
NZ598643A (en) 2013-10-25
PE20121180A1 (es) 2012-08-24
US20120251551A1 (en) 2012-10-04
CR20120113A (es) 2012-05-02
SG178919A1 (en) 2012-04-27
IN2012DN02081A (enEXAMPLES) 2015-08-21
ECSP12011716A (es) 2012-04-30
DOP2012000063A (es) 2012-05-15
BR112012005526A2 (pt) 2016-04-26
IL218390A0 (en) 2012-04-30
JP2013504523A (ja) 2013-02-07
CO6511228A2 (es) 2012-08-31
PH12012500497A1 (en) 2012-10-22
CN102639523A (zh) 2012-08-15
TN2012000108A1 (en) 2013-09-19
AU2010294588A1 (en) 2012-04-05
WO2011029537A1 (en) 2011-03-17
EP2475653A1 (en) 2012-07-18
AR078166A1 (es) 2011-10-19
MA33566B1 (fr) 2012-09-01

Similar Documents

Publication Publication Date Title
TW201111378A (en) Substituted (heteroarylmethyl) thiohydantoins
JP6534675B2 (ja) ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
CA2772790C (en) Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
US9555022B2 (en) Substituted triazolopyridines
TW201211049A (en) Substituted imidazopyridazines
JP5951750B2 (ja) 置換イミダゾピリジン類およびその中間体
JP6001049B2 (ja) Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類
WO2011063907A1 (en) Substituted triazolopyridines
TW201245194A (en) Triazolopyridines
TW201029998A (en) Substituted aryl compounds and their use
TW201200510A (en) Substituted heterocyclylbenzylpyrazoles and use thereof
JP6166289B2 (ja) 置換イミダゾピリダジン
AU2014347644B2 (en) Carboxymethyl piperidine derivative
CN103282351A (zh) 取代的苯氧基吡啶
HK1170732A (en) Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs
HK1164851A (en) Heteroaromatic compounds for use as hif inhibitors
TW201217336A (en) Chemical compounds